WEBULL
News
MOLN
4.359
+1.36%
0.059
Weekly Report: what happened at MOLN last week (1222-1226)?
Weekly Report · 12/29/2025 09:56
Weekly Report: what happened at MOLN last week (1215-1219)?
Weekly Report · 12/22/2025 09:56
Molecular Partners AG to Present Latest Developments at J.P. Morgan Healthcare Conference
Reuters · 12/18/2025 06:00
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
Barchart · 12/18/2025 00:00
Weekly Report: what happened at MOLN last week (1208-1212)?
Weekly Report · 12/15/2025 10:01
Molecular Partners forms Scientific Advisory Board
TipRanks · 12/11/2025 12:20
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
TipRanks · 12/08/2025 18:05
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
TipRanks · 12/08/2025 17:20
JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $3.75
Benzinga · 12/08/2025 16:10
Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting
TipRanks · 12/08/2025 13:27
Molecular Partners (MOLN) Receives a Buy from Clear Street
TipRanks · 12/08/2025 13:15
Molecular Partners AG Reports Positive Phase 1/2a Trial Results for MP0533 in AML
Reuters · 12/08/2025 13:10
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
TipRanks · 12/08/2025 12:41
Weekly Report: what happened at MOLN last week (1201-1205)?
Weekly Report · 12/08/2025 10:00
Reported Sunday, Molecular Partners Presents Updated MP0533 Phase 1/2a AML Data At ASH Annual Meeting With Clinical Benefit And Acceptable Safety Across Dosing Regimens
Benzinga · 12/08/2025 08:39
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
TipRanks · 12/07/2025 18:35
Molecular Partners Reports Positive Phase 1/2a Results for MP0533 in AML at ASH Meeting
Reuters · 12/07/2025 12:00
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Barchart · 12/07/2025 06:00
Weekly Report: what happened at MOLN last week (1124-1128)?
Weekly Report · 12/01/2025 09:57
Weekly Report: what happened at MOLN last week (1117-1121)?
Weekly Report · 11/24/2025 10:00
More
Webull provides a variety of real-time MOLN stock news. You can receive the latest news about MOLECULAR PARTNERS AG through multiple platforms. This information may help you make smarter investment decisions.
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.